A new study published in the journal Frontiers in Immunology explores the potential role of cannabinoids in treating triple-negative breast cancer, a particularly aggressive form of breast cancer that accounts for 10-20% of all cases.
Conducted by researchers from the University of Ljubljana and the Institute of Oncology Ljubljana in Slovenia, the study examines how cannabinoids could influence standard therapies for triple-negative breast cancer (TNBC), which has historically been treated primarily with chemotherapy.
TNBC is known for its poor prognosis and limited treatment options. Recently, immune checkpoint inhibitors have emerged as a promising systemic treatment, yet there remains a need for tumor-specific biomarkers to enhance patient outcomes. The researchers highlight that cannabinoids, which have “demonstrated antitumor activity in preclinical TNBC models”, may not only complement chemotherapy but could also serve as potential biomarkers for immune checkpoint inhibitor therapy.
“Importantly, the endocannabinoid system is linked to the immune system and immunosuppression”, states the study. “Therefore, cannabinoid receptors could be a potential biomarker for immune checkpoint inhibitor therapy or a novel mechanism to reverse resistance to immunotherapy.”
The study underscores the connection between the endocannabinoid system and the immune system, suggesting that cannabinoid receptors could play a role in reversing resistance to immunotherapy. While the findings are promising, researchers say “Clinical data are needed to evaluate efficacy and safety in humans.”
For more information on this study, click here.
